Adaptive Biotechnologies

company in Seattle, United States

ADPT Nasdaq ISIN US00650F1093 SEC CIK 1478320 LEI 549300ZTF7OT1FW66Q96
Follow Adaptive Biotechnologies Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $83.9M −10.7% vs same quarter last year
Net income $2.9M −69.9% vs same quarter last year
EPS, diluted $0.02 −66.7% vs same quarter last year
Operating cash flow $9.6M +234.8% vs same quarter last year
Revenue by quarter
$47.5M
$52.4M
$58.9M
$94M
$71.7M
$70.9M
$71.6M
$83.9M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income10 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$277M−$59.5M
FY24$179M−$159.5M
FY23$170.3M−$225.3M
FY22$185.3M−$200.2M
FY21$154.3M−$207.3M
FY20$98.4M−$146.2M
FY19$85.1M−$68.6M
FY18$55.7M−$46.4M
FY17$38.4M−$42.8M
FY16--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY17FY19FY21FY23FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2574.2%−20.6%−21.5%
FY2459.7%−90.8%−89.1%
FY2355.6%−133.3%−132.3%
FY2268.7%−108%−108%
FY2168.1%−135.4%−134.3%
FY2077.1%−155.3%−148.6%
FY1973.8%−92.1%−80.6%
FY1864.7%−89.4%−83.4%
FY1759.2%−115.7%−111.4%
FY16---
Free cash flowOperating cash flow minus capital expenditure
−$400M−$200M$0$200MFY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$48.9M
FY24−$98.9M
FY23−$167M
FY22−$200.3M
FY21−$254.5M
FY20−$168.5M
FY19$194.2M
FY18−$38.6M
FY17−$37.3M
FY16-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Adaptive Biotechnologies
  • Healthcare median
−150%−100%−50%0%FY17FY19FY21FY23FY25
Show the numbers
YearAdaptive BiotechnologiesHealthcare median
FY25−21.5%−30.6%
FY24−89.1%−47%
FY23−132.3%−58%
FY22−108%−80.4%
FY21−134.3%−71.9%
FY20−148.6%−62.2%
FY19−80.6%−46.3%
FY18−83.4%−49.6%
FY17−111.4%−45.9%
FY16-−36%